RxDoctor Payments Data

Salvador Gonzalez, MD

Family Medicine · Fresno, CANPI 1023024932

Payments from drug & device makers

$5,326in general payments, 2019–2025

Across 264 payments — averaging $20.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$561
  • AstraZeneca$416
  • Lilly USA, LLC$401
  • Novo Nordisk$341
  • Amgen$280
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$267
  • plus $3K from 39 others

What the payments were for

  • Food & beverage$5,326100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,326 in reported general payments places this provider in the 90th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$49,479
Medicare patients
108
Services billed
674

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin63$66,386
OzempicSemaglutide38$36,413
Trelegy ElliptaFluticasone/Umeclidin/Vilanter25$23,025
MounjaroTirzepatide15$18,023
EliquisApixaban26$14,809
FarxigaDapagliflozin Propanediol15$14,304
JanuviaSitagliptin Phosphate18$13,613
Synjardy XrEmpagliflozin/Metformin Hcl12$7,037
Icosapent Ethyl18$6,255
VascepaIcosapent Ethyl12$5,756
Atorvastatin Calcium484$4,306
Albuterol Sulfate HfaAlbuterol Sulfate106$3,354
Levothyroxine Sodium237$3,085
Lantus SolostarInsulin Glargine,hum.Rec.Anlog27$2,520
Gabapentin194$2,235

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Synjardy Xr$143$73,42375 claims
Novo NordiskOzempic$341$36,41338 claims
GSKTrelegy Ellipta$172$23,02525 claims
Lilly USA, LLCMounjaro$401$18,02315 claims
PfizerEliquis$197$14,80926 claims
AstraZenecaFarxiga$416$14,30415 claims
MerckJanuvia$107$13,61318 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,533 family medicine providers in California.

Other family medicine in Fresno

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →